Skip to content
Search

What if GLP-1 drugs disrupt your favourite takeaway?

New diabetes and obesity drugs are having a disruptive impact, not just across health care but also a range of other sectors and industries.

The game-changing potential of GLP-1 drugs

The introduction of GLP-1s could revolutionise health care. These drugs are not only effective in treating obesity but also have the potential to combat over 200 related diseases, promising significant long-term health savings and improved patient outcomes.

Beyond diabetes and obesity

While GLP-1 receptors are concentrated in the pancreas, evidence is growing that GLP-1 drugs can interact directly with GLP-1 receptors found in other organs.

Brain

May reduce alcohol cravings, and early evidence suggests a possible role in avoiding neurodegenerative diseases such as Alzheimer's and Parkinson's.

Liver

May reduce fat buildup in those with fatty liver disease.

Lungs        

May reduce inflammation in the lungs and other organs, although it's unclear how much of this is due to weight loss.

Kidneys

May preserve kidney function in those with chronic kidney disease.

Heart

May reduce inflammation in the heart and circulatory system.

Intestines

May speed the breakdown of fat cells to produce energy.

Will GLP-1s become the largest class of drugs in history?

The ripple effects of GLP-1s

We believe we were early in understanding the promise of GLP-1s, below are just some of the ways GLP-1s have the potential to impact various sectors beyond healthcare.

Food and beverage

GLP-1s could shift consumer preferences towards healthier choices, impacting fast food and snack industries. Alcohol consumption may also decline as these drugs help combat addictive behaviours.

Insurance

Improved health outcomes could lower healthcare costs and claims, influencing health insurance premiums and policies.

Surgery

The demand for bariatric surgery may decrease, while eligibility for knee and hip surgeries could increase as patients achieve healthier weight.

Productivity and workforce

Healthier populations could lead to enhanced productivity, reduced absenteeism, and lower healthcare costs for employers, benefiting the overall economy.

Environment

Reduced food consumption and waste could positively impact sustainability goals and reduce the carbon footprint of food production and distribution.

Dive deeper into health care innovation

Feb 2024 • GLOBAL EQUITIES

New diabetes and obesity drugs show promise for patients and investors

GLP-1 treatments are poised to reshape the health care sector.

By  Nabil Hanano, Jeffrey Holford
Jul 2024 • EQUITY

Finding the key to unlocking a US$200 billion opportunity

Company research tour: Eli Lilly

By  Nabil Hanano, Jeffrey Holford
Jul 2024 • EQUITY

Can GLP-1s and the medtech industry find a peaceful coexistence?

The success of GLP-1s in reducing weight has led some to predict industry-disruptive impacts for the medtech industry, as demand for medical devices and surgical procedures could be greatly reduced.

By  Taymour Tamaddon
Aug 2024 • ESG

Could GLP-1s help rebalance the food trilemma?

Anti-obesity medications could play a key role in balancing the food trilemma.

By  Maria Elena Drew, Daniel Ryan
Coming soon • ANALYST INSIGHT

How AI is revolutionising drug development

Large language models are learning to speak the language of biology and are being deployed in developing new drugs, both small molecule and biologics.

How to get exposure to health care

Our approach to investing is truly global. With one of the most extensive and experienced buy-side global research engines in the industry, our investment teams discover investment opportunities you can be confident in.

T. Rowe Price Global Focused Growth Equity

View Strategy Information
Low angle view of tall corporate glass skyscrapers reflecting a blue sky with white clouds

T. Rowe Price Global Growth Equity

View Strategy Information
Hand gently offering a seed to the earth, symbolizing hope, growth, and the nurturing of possibilities --ar 16:9 --style raw --stylize 250 --v 6 Job ID: 8bb1684a-35d3-41dc-b146-914a4a2aba80

T. Rowe Price Global Impact Equity

View Strategy Information

T. Rowe Price Global High Income Bond

View Strategy Information

All information is as at 31 March 2024, unless specified.

202407-3693088

Open

Audience for the document: Share Class: Language of the document:
Open Cancel

Download

Share Class: Language of the document:
Download Cancel
Sign in to manage subscriptions for products, insights and email updates.
Continue with sign in?
To complete sign in and be redirected to your registered country, please select continue. Select cancel to remain on the current site.
Continue Cancel
Once registered, you'll be able to start subscribing.

Change Details

If you need to change your email address please contact us.
Subscriptions
OK
You are ready to start subscribing.
Get started by going to our products or insights section to follow what you're interested in.

Products Insights

GIPS® Information

T. Rowe Price ("TRP") claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS standards. T. Rowe Price has been independently verified for the 27-year period ended June 30, 2023, by KPMG LLP. The verification report is available upon request. A firm that claims compliance with the GIPS standards must establish policies and procedures for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm’s policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. Verification does not provide assurance on the accuracy of any specific performance report.

TRP is a U.S. investment management firm with various investment advisers registered with the U.S. Securities and Exchange Commission, the U.K. Financial Conduct Authority, and other regulatory bodies in various countries and holds itself out as such to potential clients for GIPS purposes. TRP further defines itself under GIPS as a discretionary investment manager providing services primarily to institutional clients with regard to various mandates, which include U.S, international, and global strategies but excluding the services of the Private Asset Management group.

A complete list and description of all of the Firm's composites and/or a presentation that adheres to the GIPS® standards are available upon request. Additional information regarding the firm's policies and procedures for calculating and reporting performance results is available upon request

Other Literature

You have successfully subscribed.

Notify me by email when
regular data and commentary is available
exceptional commentary is available
new articles become available

Thank you for your continued interest